Table 1.
Clinicopathological characteristics.
| No | % | |
|---|---|---|
| Age at metastatic disease diagnosis, years | ||
| Median | 60 (range 39–78) | |
| Sex | ||
| Male | 15 | 65.2 |
| Female | 8 | 34.8 |
| Timing of metastatic disease | ||
| Synchronous | 7 | 30.4 |
| Metachronous | 16 | 69.6 |
| Extent of metastatic disease | ||
| Number of metastatic sites | ||
| 1 | 13 | 56.5 |
| 2–3 | 10 | 43.5 |
| Presence of peritoneal metastasis | ||
| No | 17 | 73.9 |
| Yes | 6 | 26.1 |
| Palliative systemic therapy | ||
| No | 4 | 17.4 |
| 1st or 2nd line | 12 | 52.2 |
| 3rd or 4th line | 7 | 17.4 |
| PGC | ||
| Primary tumor location | ||
| Gastroesophageal junction/fundus | 1 | 4.4 |
| Body | 7 | 30.4 |
| Antrum | 15 | 65.2 |
| Histological grade | ||
| Good | 11 | 47.8 |
| Poora | 12 | 52.2 |
| MGC | ||
| Surgically resected metastatic site | ||
| Liver | 6 | 26.1 |
| Abdominal wall or skin mass | 5 | 21.7 |
| Ovary | 4 | 17.4 |
| Others | 8 | 34.8 |
| Duration between gastrectomy and MGC resection | ||
| Simultaneous resection | 7 | 30.4 |
| Staged resection (≥ 6 months) | 16 | 69.6 |
| Systemic therapy within 1 year of MGC resection | ||
| Yes | 5 | 21.7 |
| No | 18 | 78.3 |
PGC primary gastric cancer, MGC metastatic gastric cancer.
aPoor histological grading defined as poorly differentiated tubular adenocarcinoma or poorly cohesive carcinoma according to the WHO classification.